The effectiveness of intranasal neostigmine (9-3-13-8 mg) was tested in 20 subjects with myasthenia gravis, classified as Osserman grades 2A and 2B. In all cases the drug produced significant clinical and electromyographic improvement. No side effects were reported during the treatment.
A new route of administration of anticholinesterase drugs in myasthenia gravis was tested by Dooley et al' in a patient with severe side effects from oral pyridostigmine. We used the nebulised form, which is likely to act principally at the cranial muscular level, resulting in improvements in facial, throat, and ocular weakness and the disappearance of the side effects. Given the high vascularity of the rhinopharynx, intranasal topical treatment could prove particularly suitable for patients whose intestinal absorption is erratic or where bulbar weakness hampers swallowing. The intranasal route avoids the hepatic first pass effect, and its pharmacokinetic profile for the small molecules is similar to the one shown by the intravenous route.2 In healthy volunteers the pharmacokinetic profile of neostigmine is similar via both routes. 3 We examined the effectiveness of intranasal neostigmine in patients with myasthenia.
consisted of a repetitive sequence of 3 Hz stimuli applied to the axillary nerve at Erb's point at the junction between the edge of the sternocleiodomastoid and the clavicle. 6 The deltoid muscle EMG activity was recorded by means of chlorinated silver-cup shaped electrodes. To prevent any artefact the patient's arm movement was restricted with elastic bands. A response was considered myasthenic when the fifth response decreased by over 10% with respect to the first one. 7 The dose of neostigmine (number of puffs) used for the test was equivalent to the dose of pyridostigmine usually taken orally. One puff (4 6 mg) of intranasal neostigmine was estimated to be equivalent to 20 mg of oral pyridostigmine. This was verified in three patients by administering doses of intranasal neostigmine at one hour intervals starting with one spray and increasing each time by one until the clinical improvement in global muscle function equalled that obtained with 60 mg oral pyridostigmine or 0-5 mg intravenous neostigmine. Three sprays were found necessary for a maximal effect.
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